公开(公告)号：US20240358647A1

公开(公告)日：2024-10-31

申请号：US18394246

申请日：2023-12-22

申请人： Oramed Ltd.

发明人： Avraham HERSHKO ,  Miriam KIDRON

IPC分类号： A61K9/48 ,  A61K9/19 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  A61K38/56 ,  A61K47/42

CPC分类号： A61K9/4866 ,  A61K9/19 ,  A61K9/4858 ,  A61K9/4875 ,  A61K9/4891 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  A61K38/56 ,  A61K47/42

摘要： Provided herein are methods and compositions for oral administration of therapeutic proteins, improved protease inhibitor preparations, methods for producing same, and compositions comprising same.

公开(公告)号：US20240350467A1

公开(公告)日：2024-10-24

申请号：US18137294

申请日：2023-04-20

申请人： Isofol Medical AB

发明人： Per Lennart Lindberg ,  David Machover

IPC分类号： A61K31/4415 ,  A61K9/00 ,  A61K9/19 ,  A61K31/282 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/4415 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/282 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61P35/00

摘要： The present invention relates to the treatment of pancreatic cancer, in particular KRAS-mutated pancreatic adenocarcinoma, in human populations employing a dosage regimen which includes arfolitixorin ([6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF) and a B6 vitamin in connection with 5-fluorouracil (5-FU) based chemotherapy.

公开(公告)号：US12121596B2

公开(公告)日：2024-10-22

申请号：US18327455

申请日：2023-06-01

申请人： Washington University

发明人： Samuel Achilefu ,  Rui Tang ,  Duanwen Shen ,  Avik Som ,  Baogang Xu ,  Gail Sudlow ,  Christopher Egbulefu ,  Partha Karmakar ,  Kexian Liang

IPC分类号： A61K49/00 ,  A61K9/00 ,  A61K9/19 ,  A61K47/42 ,  A61P35/00 ,  C09B69/10

CPC分类号： A61K49/0034 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/42 ,  A61K49/0056 ,  A61K49/0089 ,  A61P35/00 ,  C09B69/105

摘要： Provided herein is a pharmaceutical composition comprising an effective amount of cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301), cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Tyr-OH (LS838) or pharmaceutically acceptable salts thereof, wherein each amino acid residue is independently in a D or L configuration; a divalent metal ion; and a pharmaceutically acceptable carrier. Further provided are lyophilized products comprising a dye-conjugate and m methods for identifying compromised and for binding phosphorylated annexin A2 (pANXA2) protein in a biological sample using a composition described herein.

公开(公告)号：US12115229B2

公开(公告)日：2024-10-15

申请号：US17976076

申请日：2022-10-28

申请人： FIDIA FARMACEUTICI S.P.A. ,  NANOGETIC S.L.

发明人： Rosario Maria Sanchez Martin ,  Salvatore Pernagallo ,  Juan Diego Unciti Broceta ,  Luciano Messina ,  Susanna Vaccaro ,  Laura Pilotto

IPC分类号： A61K47/69 ,  A61K9/19 ,  A61K38/44 ,  A61K38/47 ,  A61K38/48 ,  A61K9/00 ,  A61K9/10

CPC分类号： A61K47/6933 ,  A61K9/19 ,  A61K38/446 ,  A61K38/47 ,  A61K38/4886 ,  A61K47/6937 ,  A61K47/6939 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0073 ,  A61K9/10

摘要： Disclosed is a nanoparticle system consisting of a polymer support or substrate in the form of nanoparticles to which a hydrolase enzyme able to degrade hyaluronic acid and one or more biologically and/or pharmacologically active molecules are covalently bonded, its preparation process and its uses in the diagnostic, prognostic and therapeutic fields.

公开(公告)号：US12109311B2

公开(公告)日：2024-10-08

申请号：US17359394

申请日：2021-06-25

申请人： Massachusetts Institute of Technology

发明人： Alexander H. Slocum ,  Bernhardt Levy Trout

IPC分类号： A61K9/19 ,  F26B5/06 ,  H02N15/00

CPC分类号： A61K9/19 ,  F26B5/06 ,  H02N15/00

摘要： System and methods related to lyophilization of pharmaceutical products are disclosed. In some embodiments, vials of product are moved through a system using one or more movers which are electromagnetically levitated and moved through the system without making mechanical contact with each other or the system. Load lock chambers may allow a mover to enter from one process region's environment and then be brought to an environment condition of the next process region to allow materials to be passed through conditioning, nucleation, and/or vacuum drying regions prior to finally exit the system to an unloading zone. The movers may then be cleaned or reloaded with vials to begin the process again with a new load of vials.

公开(公告)号：US12102710B2

公开(公告)日：2024-10-01

申请号：US17353956

申请日：2021-06-22

申请人： CROWN LABORATORIES, INC.

发明人： Thomas M. Hitchcock ,  Sasima Phadungpojna ,  Matthew D. Stephens ,  Mun Su Rhee

IPC分类号： A61K8/99 ,  A61K8/02 ,  A61K8/04 ,  A61K8/19 ,  A61K8/34 ,  A61K8/37 ,  A61K8/67 ,  A61K8/73 ,  A61K8/88 ,  A61K8/92 ,  A61K8/9789 ,  A61K9/06 ,  A61K9/19 ,  A61K31/07 ,  A61K35/741 ,  A61K47/14 ,  A61K47/34 ,  A61K47/44 ,  A61K47/46 ,  A61Q19/00

CPC分类号： A61K8/99 ,  A61K8/022 ,  A61K8/042 ,  A61K8/19 ,  A61K8/34 ,  A61K8/37 ,  A61K8/671 ,  A61K8/735 ,  A61K8/88 ,  A61K8/922 ,  A61K8/9789 ,  A61K9/06 ,  A61K9/19 ,  A61K31/07 ,  A61K35/741 ,  A61K47/14 ,  A61K47/34 ,  A61K47/44 ,  A61K47/46 ,  A61Q19/00 ,  A61K2800/524 ,  A61K2800/594

摘要： Described herein are dermatological compositions, formulations containing wild type or genetically modified Cutibacterium bacteria and methods for use thereof of skin. The cosmetic and therapeutic formulations described herein can be used as cosmetic daily skin treatments or for treating skin inflammation or disorders including acne, psoriasis, rosacea, dermatitis, or eczema.

公开(公告)号：US20240316182A1

公开(公告)日：2024-09-26

申请号：US18351512

申请日：2022-01-14

申请人： EXOLLENCE CO., LTD. ,  EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION

发明人： Ki Hwan Kwon ,  Ji Hwa Chung

IPC分类号： A61K39/215 ,  A61K9/19 ,  A61K9/50 ,  A61K39/00 ,  A61P31/14 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61K9/19 ,  A61K9/5063 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/55555 ,  A61K2039/572 ,  C12N2770/20033

摘要： The present invention relates to an extracellular vesicle including a coronavirus-derived antigen protein or a gene encoding the protein, and a use of the extracellular vesicle. According to the present invention, when mice are immunized by administering an activated immune cell-derived extracellular vesicle loaded with an antigen protein or mRNA, excellent antigen-specific neutralizing antibody production and T cell response induction effects are confirmed. When the extracellular vesicle is stored under room-temperature and refrigerated conditions after freeze-drying, high stability and an excellent antibody production effect are experimentally confirmed. From these results, the extracellular vesicle according to the present invention or a vaccine composition including the same may serve as a platform applicable to various diseases with an excellent antigen-specific immune response induction effect and excellent stability, and thus is expected to be effectively used for the development of vaccines for preventing or treating various diseases including infectious diseases, particularly coronavirus infections.

公开(公告)号：US20240316119A1

公开(公告)日：2024-09-26

申请号：US18277572

申请日：2022-02-18

申请人： VEDANTA BIOSCIENCES, INC.

发明人： Bernat Olle ,  Silvia Caballero

IPC分类号： A61K35/74 ,  A61K9/19 ,  A61K31/095 ,  A61P31/04

CPC分类号： A61K35/74 ,  A61K9/19 ,  A61K31/095 ,  A61P31/04

摘要： Provided herein are compositions and methods for suppressing infection by pathogenic organisms. Also provided herein are compositions and methods for reducing or preventing colonization by pathogenic organisms and methods of treating infection by a pathogenic organism. Also provided herein are compositions comprising taurine and methods of using such compositions for suppressing infection by pathogenic organisms, preventing colonization by pathogenic organisms, and methods of treating infection pathogenic organisms.

公开(公告)号：US12097254B2

公开(公告)日：2024-09-24

申请号：US17211632

申请日：2021-03-24

申请人： Yisheng Biopharma (Singapore) PTE LTD

发明人： Lietao Li ,  Yi Zhang ,  Fang Liu

IPC分类号： A61K39/205 ,  A61K9/19 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/205 ,  A61K9/19 ,  A61K39/12 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55561 ,  C12N2760/20134

摘要： The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a host. The rabies composition is more stable and safe, and is able to induce earlier and higher titers of neutralizing antibody.

公开(公告)号：US12083171B2

公开(公告)日：2024-09-10

申请号：US16613521

申请日：2018-05-16

申请人： OCTAPHARMA AG

发明人： Georg Lattner ,  Klaus Tschetschkowitsch ,  Almira Dugic

IPC分类号： A61K38/57 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/18

CPC分类号： A61K38/57 ,  A61K9/0029 ,  A61K9/08 ,  A61K9/19 ,  A61K47/183

摘要： The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.